Colesevelam and colestipol: Novel medication resins in the gastrointestinal tract

American Journal of Surgical Pathology

Volumn 38, Issue 11, 2014, Pages 1530-1537

  Arnold, Michael A ^a,b   Swanson, Benjamin J ^a   Crowder, Clinton D ^a   Frankel, Wendy L ^c   Lam Himlin, Dora ^d   Singhi, Aatur D ^e   Stanich, Peter P ^a   Arnold, Christina A ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^b NATIONWIDE CHILDREN S HOSPITAL   (United States)

^c MERCY MEDICAL CENTER   (United States)

^d MAYO CLINIC   (United States)

^e UNIVERSITY OF PITTSBURGH MEDICAL CENTER   (United States)

Author keywords

Bile acid sequestrant (BAS); Bile acid mediated diarrhea (BAM); Cholestyramine (LoCholest; LoCholest; Prevalite; Colesevelam (Welchol); Colestipol (Colestid); Fish scale; Gastrointestinal tract (GIT); Questran); Renagel); Resin; Sevelamer (Renvela; Sodium polystyrene sulfonate (Kayexalate)

Indexed keywords

ALLYLAMINE; COLESEVELAM; COLESTIPOL; COLESTYRAMINE; GASTROINTESTINAL AGENT; HYPOCHOLESTEROLEMIC AGENT; ION EXCHANGE RESIN;

ADULT; AGED; ANALOGS AND DERIVATIVES; BIOPSY; CHEMISTRY; CLINICAL TRIAL; DRUG EFFECTS; FEMALE; HUMAN; INTESTINE; INTESTINE MUCOSA; MALE; MIDDLE AGED; MULTICENTER STUDY; PROSPECTIVE STUDY; RISK ASSESSMENT; RISK FACTOR; UNITED STATES;

ADULT; AGED; ALLYLAMINE; ANTICHOLESTEREMIC AGENTS; BIOPSY; CHOLESTYRAMINE RESIN; COLESTIPOL; FEMALE; GASTROINTESTINAL AGENTS; HUMANS; INTESTINAL MUCOSA; INTESTINES; ION EXCHANGE RESINS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; RISK ASSESSMENT; RISK FACTORS; UNITED STATES;

EID: 84914811397     PISSN: 01475185     EISSN: 15320979     Source Type: Journal    
DOI: 10.1097/PAS.0000000000000260     Document Type: Article

References (32)

1. Abraham SC, Bhagavan BS, Lee LA, et al. Upper gastrointestinal tract injury in patients receiving kayexalate (sodium polystyrene sulfonate) in sorbitol: clinical, endoscopic, and histopathologic findings. Am J Surg Pathol. 2001;25:637-644.
2. Foresti V. Intestinal obstruction due to kayexalate in a patient concurrently treated with aluminum hydroxide and morphine sulfate. Clin Nephrol. 1994;41:252.
3. Harel Z, Harel S, Shah PS, et al. Gastrointestinal adverse events with sodium polystyrene sulfonate (Kayexalate) use: a systematic review. Am J Med. 2013; e9:24.
4. Lillemoe KD, Romolo JL, Hamilton SR, et al. Intestinal necrosis due to sodium polystyrene (Kayexalate) in sorbitol enemas: clinical and experimental support for the hypothesis. Surgery. 1987;101:267-272.
5. Rashid A, Hamilton SR. Necrosis of the gastrointestinal tract in uremic patients as a result of sodium polystyrene sulfonate (Kayexalate) in sorbitol: an underrecognized condition. Am J Surg Pathol. 1997;21:60-69.
6. Scott TR, Graham SM, Schweitzer EJ, et al. Colonic necrosis following sodium polystyrene sulfonate (Kayexalate)-sorbitol enema in a renal transplant patient. Report of a case and review of the literature. Dis Colon Rectum. 1993;36:607-609.
7. Wootton FT, Rhodes DF, Lee WM, et al. Colonic necrosis with Kayexalate-sorbitol enemas after renal transplantation. Ann Intern Med. 1989;111:947-949.
8. Swanson BJ, Limketkai BN, Liu TC, et al. Sevelamer crystals in the gastrointestinal tract (GIT): a new entity associated with mucosal injury. Am J Surg Pathol. 2013;37:1686-1693.
9. Colestipol hydrochloride, 2013. Available at: http://dailymed.nlm.nih. gov/dailymed/lookup. cfm?setid=fa6c3e11-84e9-433d-aa74-7cd34336b bed. Accessed March 7, 2014.
10. Heaton KW, Morris JS. Bitter humour: the development of ideas about bile salts. JRColl Physicians Lond. 1971;6:83-97.
11. Wedlake L, A'Hern R, Russell D, et al. Systematic review: the prevalence of idiopathic bile acid malabsorption as diagnosed by SeHCAT scanning in patients with diarrhoea-predominant irritable bowel syndrome. Aliment Pharmacol Ther. 2009;30:707-717.
12. Kuiper EM, Van Erpecum KJ, Beuers U, et al. The potent bile acid sequestrant colesevelam is not effective in cholestatic pruritus: results of a double-blind, randomized, placebo-controlled trial. Hepatology. 2010;52:1334-1340.
13. Mercado M, Mendoza-Zubieta V, Bautista-Osorio R, et al. Treatment of hyperthyroidism with a combination of methimazole and cholestyramine. J Clin Endocrinol Metab. 1996;81:3191-3193.
14. La Rosa J. Review of clinical studies of bile acid sequestrants for lowering plasma lipid levels. Cardiology. 1989;76(suppl 1):55-61; discussion 61-54.
15. Stone NJ, Robinson J, Lichtenstein AH, et al. 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol. 2013. [Epub ahead of print].
16. Fihn SD, Gardin JM, Abrams J, et al. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: executive summary: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Circulation. 2012;126:3097-3137.
17. Aldridge MA, Ito MK. Colesevelam hydrochloride: a novel bile acid-binding resin. Ann Pharmacother. 2001;35:898-907.
18. Steinmetz KL. Colesevelam hydrochloride. Am J Health Syst Pharm. 2002;59:932-939.
19. Insull W, Toth P, Mullican W, et al. Effectiveness of colesevelam hydrochloride in decreasing LDL cholesterol in patients with primary hypercholesterolemia: a 24-week randomized controlled trial. Mayo Clin Proc. 2001;76:971-982.
20. Davidson MH, Dillon MA, Gordon B, et al. Colesevelam hydrochloride (cholestagel): a new, potent bile acid sequestrant associated with a low incidence of gastrointestinal side effects. Arch Intern Med. 1999;159:1893-1900.
21. Fonseca VA, Rosenstock J, Wang AC, et al. Colesevelam HCl improves glycemic control and reduces LDL cholesterol in patients with inadequately controlled type 2 diabetes on sulfonylurea-based therapy. Diabetes Care. 2008;31:1479-1484.
22. Ooi CP, Loke SC. Colesevelam for type 2 diabetes mellitus. Cochrane Database Syst Rev. 2012;12:CD009361.
23. Goldberg RB, Fonseca VA, Truitt KE, et al. Efficacy and safety of colesevelam in patients with type 2 diabetes mellitus and inadequate glycemic control receiving insulin-based therapy. Arch Intern Med. 2008;168:1531-1540.
24. Suzuki T, Oba K, Igari Y, et al. Colestimide lowers plasma glucose levels and increases plasma glucagon-like PEPTIDE-1 (7-36) levels in patients with type 2 diabetes mellitus complicated by hypercholesterolemia. J Nippon Med Sch. 2007;74:338-343.
25. Suzuki T, Oba K, Igari Y, et al. Effects of bile-acid-binding resin (colestimide) on blood glucose and visceral fat in Japanese patients with type 2 diabetes mellitus and hypercholesterolemia: an open-label, randomized, case-control, crossover study. J Diabetes Complications. 2012;26:34-39.
26. Takeuchi A, Sano N, Takikawa H. Inhibition of ileal bile acid absorption by colestimide. J Gastroenterol Hepatol. 2003;18:548-553.
27. Hutcheon DF, Bayless TM, Gadacz TR. Postcholecystectomy diarrhea. JAMA. 1979;241:823-824.
28. Arlow FL, Dekovich AA, Priest RJ, et al. Bile acid-mediated postcholecystectomy diarrhea. Arch Intern Med. 1987;147:1327-1329.
29. Chande N, McDonald JW, Macdonald JK. Interventions for treating collagenous colitis. Cochrane Database Syst Rev. 2008; CD003575.
30. Ung KA, Gillberg R, Kilander A, et al. Role of bile acids and bile acid binding agents in patients with collagenous colitis. Gut. 2000;46:170-175.
31. Steuerwald M, Bucher HC, Müller-Brand J, et al. HIV-enteropathy and bile acid malabsorption: response to cholestyramine. Am J Gastroenterol. 1995;90:2051-2053.
32. Cramp ME, Hing MC, Marriott DJ, et al. Bile acid malabsorption in HIV infected patients with chronic diarrhoea. Aust NZJ Med. 1996;26:368-371.